文献速递浆细胞疾病

LocoMMotion:三联暴露复发/难治性多发性骨髓瘤患者真实世界现行标准治疗研究——2年随访(最终分析)

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).
PubMed 文献 · Leukemia · 2024-09-25

LocoMMotion是首个在真实世界临床实践(RWCP)中前瞻性研究三联暴露(TCE)复发/难治性多发性骨髓瘤(RRMM)患者的研究,最终分析中位随访26.4个月(范围0.1-35.0)。248例患者入组时中位既往治疗线数为4(范围2-13),索引治疗线使用了91种独特方案,总缓解率31.9%(95%CI 26.1-38.0),中位无进展生存期4.6个月(95%CI 3.9-5.6),中位总生存期13.8个月(95%CI 10.8-17.0)。152例(61.3%)接受了后续治疗线,共134种独特方案,其中78种用于首次后续治疗线;中位PFS2为10.8个月(95%CI 8.4-13.0)。158例在研究期间死亡,67.7%死于疾病进展。研究结论指出,RWCP中治疗方案数量多且临床结局差,证实TCE RRMM患者缺乏标准化治疗,凸显了对新机制治疗的需求。

要点

  • TCE RRMM患者真实世界索引治疗线使用91种独特方案,总缓解率31.9%。
  • 中位PFS 4.6个月,中位OS 13.8个月,中位PFS2 10.8个月。
  • 158例死亡,67.7%死于疾病进展,证实缺乏标准化治疗。

核心结论

  • RWCP中治疗方案数量多且临床结局差,证实TCE RRMM患者缺乏标准化治疗,凸显对新机制治疗的需求。

研究设计与样本

  • LocoMMotion是首个在TCE RRMM患者中前瞻性研究真实世界临床实践的研究,最终分析中位随访26.4个月(范围0.1-35.0),共纳入248例患者,入组时中位既往治疗线数为4(范围2-13)。

主要发现

  • 索引治疗线共使用91种独特方案,总缓解率31.9%(95%CI 26.1-38.0)。
  • 中位无进展生存期4.6个月(95%CI 3.9-5.6),中位总生存期13.8个月(95%CI 10.8-17.0)。
  • 152例(61.3%)接受了后续治疗线,共134种独特方案,其中78种用于首次后续治疗线;中位PFS2为10.8个月(95%CI 8.4-13.0)。
  • 158例在研究期间死亡,67.7%死于疾病进展。
  • 报告了额外的亚组分析和长期安全性总结。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1-35.0). Patients (N = 248) had received median 4 prior LOT (range, 2-13) at enrollment. 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI, 26.1-38.0), median progression-free survival (PFS) was 4.6 months (95% CI, 3.9-5.6) and median overall survival was 13.8 months (95% CI, 10.8-17.0). 152 patients (61.3%) had subsequent LOTs with 134 unique regimens, of which 78 were used in first subsequent LOT. Median PFS2 (from start of study through first subsequent LOT) was 10.8 months (95% CI, 8.4-13.0). 158 patients died on study, 67.7% due to progressive disease. Additional subgroup analyses and long-term safety summaries are reported. The high number of RWCP treatment regimens utilized and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis). Leukemia. 2024. PMID: 39322709. doi:10.1038/s41375-024-02404-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。